Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, BioNeurology and Elan Drug Technologies (EDT). The BioNeurology segment engages in the research, development, and commercial activities primarily in the areas of Alzheimer?s disease, Parkinson?s disease, multiple sclerosis (MS), Crohn?s disease, and severe chronic pain. Its offers Tysabri to treat relapsing forms of MS; Prialt, a non-opioid and intrathecal analgesic for the treatment of severe chronic pain, principally neuropathic pain; Azactam, a monobactam to treat pneumonia, post-surgical infections, and septicemia; and Maxipime, an injectable cephalosporin antibiotic used to treat patients with serious and/or life-threatening infections. This segment in collaboration with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn?s disease. It also develops beta amyloid immunotherapies for the treatment of Alzheimer?s disease through collaboration with Wyeth. In addition, this segment develops ELND005, a novel therapeutic agent, which is in Phase II clinical study to treat Alzheimer?s disease; ELND006, a small molecule gamma secretase inhibitor is in Phase I clinical studies for the treatment of Alzheimer?s disease; and Beta secretase, a precursor to plaque development in the brain. Further, BioNeurology segment has collaboration agreement with PharmatrophiX to develop small molecule ligands for growth factor receptors relevant to neurological disorders. The EDT segment offers pharmaceutical products using its proprietary drug technologies. It also provides formulation development services and contract manufacturing services that include analytical development, clinical trial manufacturing, scale-up, product registration support, and supply chain management. Elan Corporation sells its products primarily to drug wholesalers. The company was founded in 1969 and is headquartered in Dublin, Ireland.
